What Is the Alluvi BPC-157 TB500 40mg Pen?
The Alluvi BPC-157 TB500 40mg Pen is a Synedica-certified, pre-filled dual peptide research injection pen delivering 40mg of two of the most extensively studied tissue repair and regenerative peptides in modern research — Body Protection Compound 157 (BPC-157) and Thymosin Beta-500 (TB-500) — combined in a single precision-engineered pre-filled pen. Supplied exclusively by Alluvi Healthcare as part of the Synedica-certified research pen range, the BPC-157 TB500 40mg pen is the definitive recovery and repair research tool for UK laboratories investigating tendon, ligament, muscle and connective tissue regeneration, wound healing biology, neuroregeneration and systemic tissue repair mechanisms.
BPC-157 — a pentadecapeptide derived from a protective gastric juice protein — has been the subject of over 30 years of pre-clinical research demonstrating remarkable tissue-healing and cytoprotective properties across multiple organ systems. TB-500 — a synthetic analogue of Thymosin Beta-4 — is one of the most potent actin-regulating peptides known to biology, playing a critical role in cell migration, tissue repair and angiogenesis. Together in the Alluvi BPC-157 TB500 40mg pen, these two complementary peptides form the most comprehensive dual-peptide recovery and repair research tool available from a UK domestic source. UK researchers searching for the most verified, reliably dispatched BPC-157 TB500 UK research pen will find everything they need at Alluvi Healthcare.
The Science — BPC-157 & TB500 Dual Peptide Mechanism
The scientific rationale for combining BPC-157 and TB500 in a single research pen lies in their complementary and synergistic mechanisms of action across the tissue repair cascade. BPC-157 acts primarily through upregulation of the FAK-paxillin pathway, VEGFR2-mediated angiogenesis, and NO-system modulation — accelerating wound healing, tendon-to-bone integration, and mucosal tissue repair. TB-500 acts through actin sequestration, promoting cell migration and differentiation, stimulating angiogenesis through VEGF upregulation and activating anti-inflammatory pathways. Together they address the tissue repair cascade from multiple angles simultaneously — making the Alluvi BPC-157 TB500 40mg pen the most mechanistically complete recovery research tool available in the UK today.
Key Research Mechanisms — BPC-157
- Tendon and ligament repair: BPC-157 has demonstrated accelerated tendon-to-bone healing and ligament repair in pre-clinical models — among the most cited applications in BPC-157 research literature
- Gastrointestinal cytoprotection: BPC-157 demonstrates potent protective and regenerative effects on gastric mucosa, intestinal epithelium and IBD-related tissue damage models
- Angiogenesis: BPC-157 upregulates VEGFR2 expression and promotes neovascularisation — critical for tissue repair and wound healing research
- Neuroregeneration: BPC-157 has demonstrated neuroprotective and neuroregenerative effects in models of traumatic brain injury, spinal cord injury and peripheral nerve damage
- Muscle healing: Accelerated skeletal muscle repair following crush injury, transection and ischaemia-reperfusion in pre-clinical models
- NO system modulation: BPC-157 modulates nitric oxide signalling — relevant to cardiovascular, anti-inflammatory and tissue repair research
Key Research Mechanisms — TB500 (Thymosin Beta-4)
- Actin regulation: TB-500 sequesters G-actin, modulating cell cytoskeleton dynamics and enabling cell migration — the fundamental mechanism underlying its tissue repair effects
- Wound healing: TB-500 accelerates dermal wound closure through keratinocyte and fibroblast migration — one of the most replicated findings in Thymosin Beta-4 research
- Cardiac repair: TB-500 has demonstrated cardioprotective and cardiac regenerative effects in ischaemia-reperfusion models — a significant area of UK cardiovascular research
- Anti-inflammatory: TB-500 downregulates inflammatory cytokines including TNF-α and IL-1β — relevant to chronic inflammation and autoimmune research models
- Angiogenesis: TB-500 promotes angiogenesis through VEGF upregulation, complementing BPC-157’s VEGFR2-mediated mechanisms
- Hair follicle regeneration: TB-500 stimulates hair follicle stem cell activity — an emerging area of cosmetic and dermatological research
Full Technical Specifications — Alluvi BPC-157 TB500 40mg
| Product Name | Alluvi BPC-157 TB500 40mg (Synedica) |
| Manufacturer | Synedica (distributed by Alluvi Healthcare UK) |
| Active Compounds | BPC-157 (Body Protection Compound) + TB-500 (Thymosin Beta-500) |
| Compound Class | Dual Peptide · Recovery & Repair · Tissue Regeneration |
| Total Per Pen | 40mg (4 × 10mg doses) |
| Dose Structure | 4 × 10mg per pen (precision click-dial mechanism) |
| Micro-Dose Increments | 2.5mg · 5mg · 7.5mg · 10mg per dose |
| Delivery Format | Pre-filled subcutaneous injection pen |
| Needles Included | 6 × fine-gauge subcutaneous pen needles |
| Purity Standard | ≥98% — independent third-party analytical verification |
| Certificate of Analysis | Batch-specific COA included with every order |
| Certification | Synedica — pharmaceutical-grade manufacturing standard |
| Storage — Unopened | Refrigerated 2–8°C · Away from direct light · Do not freeze |
| Storage — In Use | Refrigerate between uses · Use within stated stability window |
| Dispatch Method | Cold-chain insulated packaging · UK domestic stock |
| Dispatch Timeframe | Within 48 hours of order confirmation |
| Delivery Coverage | All UK addresses — mainland + highlands |
| Research Application | Tissue repair · Recovery · Tendon/ligament biology · Neuroregeneration · Wound healing |
| Regulatory Status | Research use only — not MHRA licensed for clinical use |
BPC-157 TB500 vs Single-Peptide Recovery Research
UK researchers frequently ask whether to use BPC-157 or TB-500 independently — or together. The Alluvi BPC-157 TB500 40mg pen answers this question definitively by combining both peptides in a single Synedica-certified pen, providing the dual-mechanism coverage that single-peptide research cannot match.
| Feature | Alluvi BPC-157 TB500 40mg | BPC-157 Only | TB500 Only |
|---|---|---|---|
| Peptide Coverage | BPC-157 + TB-500 (dual) | BPC-157 only | TB-500 only |
| Tissue Repair | ✓ Full cascade | Partial coverage | Partial coverage |
| Angiogenesis | ✓ VEGFR2 + VEGF dual | VEGFR2 only | VEGF only |
| Anti-inflammatory | ✓ Both pathways | Limited | TNF-α / IL-1β |
| Synedica Certified | ✓ Yes | Varies by source | Varies by source |
| COA ≥98% | ✓ Yes | Varies | Varies |
| 48hr UK Dispatch | ✓ Yes | Varies | Varies |
| Order | Buy Now → | — | — |
Research Applications — What UK Laboratories Are Investigating
- Musculoskeletal injury repair: Tendon, ligament and muscle healing research — among the most active applications of BPC-157 and TB-500 in UK pre-clinical biology
- Wound healing biology: Investigating the full wound repair cascade including haemostasis, inflammation, proliferation and tissue remodelling phases
- Neuroregeneration: BPC-157 and TB-500 effects on peripheral nerve regeneration, spinal cord repair and traumatic brain injury recovery models
- Gastrointestinal research: BPC-157 cytoprotection in IBD, leaky gut, gastric ulcer and intestinal epithelial repair models — a major area of UK gastroenterology research
- Cardiovascular repair: TB-500 cardiac regeneration and BPC-157 NO-mediated cardiovascular protection in ischaemia-reperfusion models
- Inflammatory disease models: Dual anti-inflammatory mechanisms of BPC-157 and TB-500 in arthritis, autoimmune and chronic inflammation research designs
- Dermatological and hair research: TB-500 hair follicle regeneration and BPC-157 skin wound healing in cosmetic and dermatological research
- Combination protocols: Widely paired with Alluvi Retatrutide 40mg Pen and Alluvi NAD+ 1000mg in comprehensive multi-compound longevity and metabolic research programmes
Why Choose Alluvi Healthcare for BPC-157 TB500 Research UK
UK researchers searching for BPC-157 TB500 UK, Alluvi BPC-157, or the most verified dual-peptide recovery pen consistently choose Alluvi Healthcare. As Britain’s most trusted Synedica-certified research compound pen supplier, Alluvi Healthcare delivers Synedica certification, ≥98% independently verified purity, pre-filled pen format, 48hr UK cold-chain dispatch, WhatsApp research support on +44 7537 823566, and the full range from a single UK source.
How to Order — Alluvi BPC-157 TB500 40mg
- Visit alluviukshop.co.uk/shop and select the Alluvi BPC-157 TB500 40mg Pen
- Consider adding the Alluvi Retatrutide 40mg Pen, Alluvi NAD+ 1000mg or Alluvi Glow 70mg for a comprehensive multi-compound research protocol
- Apply code alluvicare26 at checkout for 35% off — applied automatically on first orders
- Receive within 48 hours — cold-chain dispatched in discreet unmarked packaging with full tracking
- Refrigerate immediately at 2–8°C and verify the batch COA before beginning your research protocol
Storage & Handling
- Refrigerate immediately on receipt at 2–8°C
- Do not freeze — freezing permanently degrades peptide structure
- Protect from direct light — store in original packaging inside the refrigerator
- Do not shake or agitate — handle gently at all times
- Verify COA batch number before beginning any research protocol
- Note the expiry date printed on the pen body and outer packaging
- Inspect before use — if cloudy, discoloured or contains particulates do not use. Contact Alluvi Healthcare via WhatsApp immediately
Explore the Complete Alluvi Healthcare Research Range
- Alluvi Retatrutide 40mg Pen — Triple GLP-1/GIP/Glucagon · Synedica · 4×10mg · ≥98% COA
- Alluvi Retatrutide 20mg Pen — Initiation phase triple agonist · Synedica · 2×10mg
- Alluvi Tirzepatide 20mg Pen — Dual GLP-1/GIP agonist · Synedica · 2×10mg · ≥98% COA
- Alluvi Glow 70mg — BPC-157 + TB500 + GHK-Cu tri-peptide · Skin · hair · cellular repair
- Alluvi NAD+ 1000mg — Brain cellular repair · Anti-ageing · 2×500mg · ≥98% COA
- Wholesale Orders — Bulk supply for UK laboratories
- Alluvi Healthcare Blog — Research insights, reviews and sourcing guides
⚠️ Research Use Only — Legal Disclaimer: The Alluvi BPC-157 TB500 40mg Pen is supplied exclusively for legitimate scientific laboratory research, analytical testing and formulation development. Not licensed as a medicine by the MHRA or any other regulatory body. Not for human consumption, self-administration, veterinary use or clinical application outside of authorised clinical trials. By purchasing, the buyer confirms they are a qualified researcher aged 18 or above operating in full compliance with all applicable UK regulations. For regulatory guidance visit MHRA.gov.uk. For clinical context visit NICE.org.uk.
Reviews
There are no reviews yet.